Vnitr Lek 2019, 65(2):76-80 | DOI: 10.36290/vnl.2019.019

Defensive and damaging inflammation: basic characteristics

Jan Krejsek
Ústav klinické imunologie a alergologie LF UK a FN Hradec Králové

Immune system is the integral part of the complex body response, inflammation, which is raised either by the exposure to external signals, predominantly pathogens or by damage of own structures. Predominantly innate immunity is equiped by the receptors recognizing pathogenic PAMPs or signals of own damage DAMPs. The inflammatory response is reflecting the actual demand of our body. The potential of the inflammatory response is so powerful that its intensity and extent have to be carefully regulated on many levels.

Keywords: homeostasis; inflammation; PRR receptors; signals PAMP, DAMP

Received: September 17, 2018; Accepted: November 26, 2018; Published: February 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krejsek J. Defensive and damaging inflammation: basic characteristics. Vnitr Lek. 2019;65(2):76-80. doi: 10.36290/vnl.2019.019.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Krejsek J, Andrýs C, Krčmová I. Imunologie člověka. Garamon: Hradec Králové 2016. ISBN 978-80-86472-74-4.
    2. Matsumoto M, Takeda Y, Tatematsu M et al. Toll-like receptor 3 signal in dendritic cells benefits cancer immunotherapy. Front Immunol 2017; 8: 1897. Dostupné z DOI: <http://dx.doi.org/10.3389/fimmu.2017.01897>. Go to original source... Go to PubMed...
    3. Oczypok EA, Perkins TN, Oury TD. All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatr Respir Rev 2017; 23: 40-49. Dostupné z DOI: <http://dx.doi.org/10.1016/j.prrv.2017.03.012>. Go to original source... Go to PubMed...
    4. Dominguez-Martinez DA, Nunez-Avellaneda D, Castanon-Sanchez CA et al. NOD2: Activation during bacterial and viral infections, polymorphisms and potential as therapeutic target. Rev Invest Clin 2018; 70(1): 18-28. Dostupné z DOI: <http://dx.doi.org/10.24875/RIC.17002327>. Go to original source... Go to PubMed...
    5. Coutermarsh-Ott S, Eden K, Allen IC. Beyond the inflammasome: regulatory NOD-like receptor modulation of the host immune response following virus exposure. J Gen Virol 2016; 97(4): 825-838. Dostupné z DOI: <http://dx.doi.org/10.1099/jgv.0.000401>. Go to original source... Go to PubMed...
    6. Cronkite DA, Strutt TM. The regulation of inflammation by innate and adaptive lymphocytes. J Immunol Res 2018:1467538. Dostupné z DOI: <http://dx.doi.org/10.1155/2018/1467538>. Go to original source... Go to PubMed...
    7. Domogalla MP, Rostan PV, Raker VK et al. Tolerance through education: how tolerogenic dendritic cells shape immunity. Front Immunol 2017; 8: 1764. Dostupné z DOI: <http://dx.doi.org/10.3389/fimmu.2017.01764>. Go to original source... Go to PubMed...
    8. Cruz MS, Diamond A, Russell A et al. Human αβ and γδ T cells in skin immunity and disease. Frontiers Immunol 2018; 9: 1304. Dostupné z DOI: <http://dx.doi.org/10.3389/fimmu.2018.01304>. Go to original source... Go to PubMed...
    9. Kuwabara T, Ishikawa F, Kondo M et al. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm 2017: 3908061. Dostupné z DOI: http://dx.doi.org/10.1155/2017/3908061 Go to original source... Go to PubMed...
    10. Timmermans K, Kox M, Scheffer GJ et al. Danger in the intensive care unit: DAMPs in critically ill patients. Shock 2016; 45(2): 108-116. Dostupné z DOI: <http://dx.doi.org/10.1097/SHK.0000000000000506>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.